Bayside BioSciences is a biotech startup located in the heart of Silicon Valley, founded in 2010. The company specializes in providing preclinical services for the biotech and pharmaceutical industries, aiming to streamline their drug development processes. Bayside BioSciences offers a comprehensive range of services, including bioanalytic, molecular and cell biology, in vitro and in vivo pharmacology, as well as assay development and in vitro/in vivo pharmacology studies for various pharmaceutical products such as antibodies, small molecules, siRNAs, proteins, and gene therapy products.
The company is dedicated to supporting clients' preclinical development needs and prides itself on maintaining a high degree of flexibility to accommodate tight timelines and optimize study outcomes. Bayside BioSciences emphasizes collaboration with sponsors to ensure that studies can be initiated swiftly and adjusted when necessary.
As a contract provider, Bayside BioSciences positions itself as a one-stop solution for companies in the biotech and pharmaceutical sectors, offering a range of essential services that are crucial for the advancement of new drug candidates. While specific details about the last investment and investors are not available at this time, the company’s strategic location and focus on providing essential services to the biotech and pharmaceutical industries make it an intriguing prospect for potential venture capital investments.
